CXCL10 and Alzheimer disease: To examine whether erlotinib modulates the AD-associated reactive astrocyte population, 3.5-month-old 5xFAD mice and WT mice were administered vehicle (5% DMSO + 10% PEG + 20% Tween80 + 65% D.W.)or erlotinib (20 mg/kg, i.p.)daily for 14 days, and immunofluorescence staining of brain slices was conducted with an anti-CXCL10 antibody to detect reactive astrocytes.